Pankaj Gupta, MBBS, MD, FACP - VA Long ...

Dr. Pankaj Gupta

Claim this profile

Tibor Rubin VA Medical Center

Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
14 reported clinical trials
30 drugs studied

Area of expertise

1

Lung Cancer

Pankaj Gupta has run 6 trials for Lung Cancer. Some of their research focus areas include:

Stage II
Stage I
Stage III
2

Non-Small Cell Lung Cancer

Pankaj Gupta has run 5 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:

Stage II
Stage I
Stage III

Affiliated Hospitals

Image of trial facility.

Tibor Rubin VA Medical Center

Image of trial facility.

V.A. Long Beach Healthcare System

Clinical Trials Pankaj Gupta is currently running

Image of trial facility.

Carboplatin + Cabazitaxel

for Prostate Cancer

This phase III trial compares the effect of adding carboplatin to the standard of care chemotherapy drug cabazitaxel versus cabazitaxel alone in treating prostate cancer that keeps growing even when the amount of testosterone in the body is reduced to very low levels (castrate-resistant) and that has spread from where it first started (primary site) to other places in the body (metastatic). Carboplatin is in a class of medications known as platinum-containing compounds. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Chemotherapy drugs, such as cabazitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Prednisone is often given together with chemotherapy drugs. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs and to help the chemotherapy work. Giving carboplatin with the standard of care chemotherapy drug cabazitaxel may be better at treating metastatic castrate-resistant prostate cancer.

Recruiting

2 awards

Phase 3

5 criteria

Image of trial facility.

Azacytidine + Romidepsin

for Peripheral T-Cell Lymphoma

This trial is testing if a combination of two drugs, romidepsin and azacytidine, is safe and effective for patients with aggressive Peripheral T-Cell Lymphoma that hasn't responded to other treatments. The goal is to see if this combination works better than using just one drug alone. Romidepsin is approved for certain types of T-cell lymphoma and has shown positive results in various T-cell cancers.

Recruiting

1 award

Phase 2

11 criteria

More about Pankaj Gupta

Clinical Trial Related

7 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 7 Active Clinical Trials

Treatments Pankaj Gupta has experience with

  • Biospecimen Collection
  • Carboplatin
  • Pembrolizumab
  • Pemetrexed Disodium
  • Gemcitabine Hydrochloride
  • Prophylactic Cranial Irradiation

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Pankaj Gupta specialize in?

Is Pankaj Gupta currently recruiting for clinical trials?

Are there any treatments that Pankaj Gupta has studied deeply?

What is the best way to schedule an appointment with Pankaj Gupta?

What is the office address of Pankaj Gupta?

Is there any support for travel costs?